The ongoing policy debate about pharmaceutical and biologic patents has been coopted by those who don’t like patents—including those who have a financial incentive not to like patents. These paid mercenaries concoct and then disseminate fraudulent “reports”, which have become the lifeblood for patent critics. Even when the inaccuracies and lies are clearly identified, the cacophony of patent haters drowns out the truth thanks to a complicit, ideologically aligned popular press that continues to cite and rely on fabricated “findings” that couldn’t stand up to the scrutiny of your average fifth grader.
The post Amgen Attacks Academics’ False Claims About Biologic Patents appeared first on IPWatchdog.com | Patents & Intellectual Property Law.
Recent Posts
- Other Barks & Bites for Friday, November 7: CJEU Action Against EU Commission Referred Over SEP Regulation; Ninth Circuit Affirms CoComelon Copyright Win; and C4IP Urges USTR to Address IP Concerns in USMCA Joint Review
- Mixed UK High Court Ruling Fails to Answer Fundamental Questions of AI Copyright Infringement
- Professors Press SCOTUS to Affirm Copyright Protection for AI-Created Works
- Squires Emphasizes AI, Dubs Inherited Backlog ‘An Absolute Dumpster Fire’ and a ‘Betrayal’
- Federal Circuit Clarifies Precedent on Pre-AIA Prior Art ‘By Another’
